A phase 1/2 trial of Gemcitabine + nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Onconic Therapeutics Inc., now recruiting.
Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer is a phase 1/2 interventional study registered as NCT05257993 by Onconic Therapeutics Inc., with 71 participants planned, started 2022-03-30 and due to reach its primary completion in 2030-04. Interventions recorded: JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel. Conditions listed: Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Shares Gemcitabine + nab-paclitaxel, Metastatic pancreatic ductal adenocarcinoma, Cytotoxic chemotherapy.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/